JSKN 033
Alternative Names: JSKN-033Latest Information Update: 11 Mar 2024
At a glance
- Originator Jiangsu Alphamab Biopharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 02 Feb 2024 Preclinical trials in Solid tumours in China (SC) (Jiangsu Alphamab Biopharmaceutical pipeline, January 2024)
- 18 Jan 2024 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in Australia (SC) (NCT06226766)
- 18 Jan 2024 Jiangsu Alphamab Biopharmaceuticals plans a phase I/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (SC) (NCT06226766)